Cargando…

Continuous Activity Assay for HDAC11 Enabling Reevaluation of HDAC Inhibitors

[Image: see text] Histone deacetylase 11 (HDAC11) preferentially removes fatty acid residues from lysine side chains in a peptide or protein environment. Here, we report the development and validation of a continuous fluorescence-based activity assay using an internally quenched TNFα-derived peptide...

Descripción completa

Detalles Bibliográficos
Autores principales: Kutil, Zsófia, Mikešová, Jana, Zessin, Matthes, Meleshin, Marat, Nováková, Zora, Alquicer, Glenda, Kozikowski, Alan, Sippl, Wolfgang, Bařinka, Cyril, Schutkowski, Mike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2019
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882135/
https://www.ncbi.nlm.nih.gov/pubmed/31788622
http://dx.doi.org/10.1021/acsomega.9b02808
_version_ 1783474088555053056
author Kutil, Zsófia
Mikešová, Jana
Zessin, Matthes
Meleshin, Marat
Nováková, Zora
Alquicer, Glenda
Kozikowski, Alan
Sippl, Wolfgang
Bařinka, Cyril
Schutkowski, Mike
author_facet Kutil, Zsófia
Mikešová, Jana
Zessin, Matthes
Meleshin, Marat
Nováková, Zora
Alquicer, Glenda
Kozikowski, Alan
Sippl, Wolfgang
Bařinka, Cyril
Schutkowski, Mike
author_sort Kutil, Zsófia
collection PubMed
description [Image: see text] Histone deacetylase 11 (HDAC11) preferentially removes fatty acid residues from lysine side chains in a peptide or protein environment. Here, we report the development and validation of a continuous fluorescence-based activity assay using an internally quenched TNFα-derived peptide derivative as a substrate. The threonine residue in the +1 position was replaced by the quencher amino acid 3′-nitro-l-tyrosine and the fatty acyl moiety substituted by 2-aminobenzoylated 11-aminoundecanoic acid. The resulting peptide substrate enables fluorescence-based direct and continuous readout of HDAC11-mediated amide bond cleavage fully compatible with high-throughput screening formats. The Z′-factor is higher than 0.85 for the 15 μM substrate concentration, and the signal-to-noise ratio exceeds 150 for 384-well plates. In the absence of NAD(+), this substrate is specific for HDAC11. Reevaluation of inhibitory data using our novel assay revealed limited potency and selectivity of known HDAC inhibitors, including Elevenostat, a putative HDAC11-specific inhibitor.
format Online
Article
Text
id pubmed-6882135
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-68821352019-11-29 Continuous Activity Assay for HDAC11 Enabling Reevaluation of HDAC Inhibitors Kutil, Zsófia Mikešová, Jana Zessin, Matthes Meleshin, Marat Nováková, Zora Alquicer, Glenda Kozikowski, Alan Sippl, Wolfgang Bařinka, Cyril Schutkowski, Mike ACS Omega [Image: see text] Histone deacetylase 11 (HDAC11) preferentially removes fatty acid residues from lysine side chains in a peptide or protein environment. Here, we report the development and validation of a continuous fluorescence-based activity assay using an internally quenched TNFα-derived peptide derivative as a substrate. The threonine residue in the +1 position was replaced by the quencher amino acid 3′-nitro-l-tyrosine and the fatty acyl moiety substituted by 2-aminobenzoylated 11-aminoundecanoic acid. The resulting peptide substrate enables fluorescence-based direct and continuous readout of HDAC11-mediated amide bond cleavage fully compatible with high-throughput screening formats. The Z′-factor is higher than 0.85 for the 15 μM substrate concentration, and the signal-to-noise ratio exceeds 150 for 384-well plates. In the absence of NAD(+), this substrate is specific for HDAC11. Reevaluation of inhibitory data using our novel assay revealed limited potency and selectivity of known HDAC inhibitors, including Elevenostat, a putative HDAC11-specific inhibitor. American Chemical Society 2019-11-15 /pmc/articles/PMC6882135/ /pubmed/31788622 http://dx.doi.org/10.1021/acsomega.9b02808 Text en Copyright © 2019 American Chemical Society This is an open access article published under an ACS AuthorChoice License (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes.
spellingShingle Kutil, Zsófia
Mikešová, Jana
Zessin, Matthes
Meleshin, Marat
Nováková, Zora
Alquicer, Glenda
Kozikowski, Alan
Sippl, Wolfgang
Bařinka, Cyril
Schutkowski, Mike
Continuous Activity Assay for HDAC11 Enabling Reevaluation of HDAC Inhibitors
title Continuous Activity Assay for HDAC11 Enabling Reevaluation of HDAC Inhibitors
title_full Continuous Activity Assay for HDAC11 Enabling Reevaluation of HDAC Inhibitors
title_fullStr Continuous Activity Assay for HDAC11 Enabling Reevaluation of HDAC Inhibitors
title_full_unstemmed Continuous Activity Assay for HDAC11 Enabling Reevaluation of HDAC Inhibitors
title_short Continuous Activity Assay for HDAC11 Enabling Reevaluation of HDAC Inhibitors
title_sort continuous activity assay for hdac11 enabling reevaluation of hdac inhibitors
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882135/
https://www.ncbi.nlm.nih.gov/pubmed/31788622
http://dx.doi.org/10.1021/acsomega.9b02808
work_keys_str_mv AT kutilzsofia continuousactivityassayforhdac11enablingreevaluationofhdacinhibitors
AT mikesovajana continuousactivityassayforhdac11enablingreevaluationofhdacinhibitors
AT zessinmatthes continuousactivityassayforhdac11enablingreevaluationofhdacinhibitors
AT meleshinmarat continuousactivityassayforhdac11enablingreevaluationofhdacinhibitors
AT novakovazora continuousactivityassayforhdac11enablingreevaluationofhdacinhibitors
AT alquicerglenda continuousactivityassayforhdac11enablingreevaluationofhdacinhibitors
AT kozikowskialan continuousactivityassayforhdac11enablingreevaluationofhdacinhibitors
AT sipplwolfgang continuousactivityassayforhdac11enablingreevaluationofhdacinhibitors
AT barinkacyril continuousactivityassayforhdac11enablingreevaluationofhdacinhibitors
AT schutkowskimike continuousactivityassayforhdac11enablingreevaluationofhdacinhibitors